Lymphoma Clinical Trials & Research

Our mission has always been a singular one: to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments, and many of our innovations and approaches have set the standard for care. We won’t give up until we conquer cancer.

In fact, we’re currently studying new approaches to treating lymphoma, and we come closer to finding exciting solutions every day. One of the most important goals we have is to develop new and improved treatments for people with lymphoma who are not helped by standard treatments.

Our doctors are leading a large number of clinical trials to test new drugs and drug combinations. We’re on the hunt for genetic factors linked to lymphoma development and other strategies for improving treatment. These research studies are based on our growing understanding of how lymphoma is different from other cancers, and the research is increasingly “translational,” meaning that discoveries made in the lab are taken directly to our patients.

In other words, choosing MSK may give you access to new treatment options before they’re widely available elsewhere. We have extensive experience in matching patients with the right clinical trials that will benefit them the most.

We do research in:

  • New chemotherap​y approaches
    Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.
  • Pathway-directed (biologic) therapies
    Our investigators are testing drugs that are designed to interrupt or restrain the molecular processes that tumor cells require to grow and spread.
  • Immune strategies
    We’re testing investigational drugs aimed at encouraging the body’s immune system to identify and react against cancer cells.

Marginal Zone Lymphoma

Follicular Lymphoma

Untreated (Newly Diagnosed)

A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma
Anas Younes
[Protocol 16-006]

A Pilot Study of Ibrutinib in Patients with Evidence of Follicular Lymphoma after Initial Treatment
Ariela Noy
[Protocol 16-396]

Prior Treatment (Relapsed/Refractory)

A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma
Anas Younes
[Protocol 16-006]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase IB Study of BCL201 and Idelalisib in Patients with Recurrent or Persistent Follicular Lymphoma and Mantle Cell Lymphoma
Anas Younes
[Protocol 15-333]

A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
John F. Gerecitano
[Protocol 16-873]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
John F. Gerecitano
[Protocol 15-236]

A Phase I Study of JNJ-64052781 in Patients with Recurrent or Persistent B-Cell Cancers
Anas Younes
[Protocol 15-125]

A Phase I/II Study of Lenalidomide plus Obinutuzumab and Atezolizumab Immunotherapy in Patients with Recurrent or Persistent Follicular Lymphoma
M. Lia Palomba
[Protocol 16-799]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

Small Lymphocytic Lymphoma (SLL)

Diffuse Large B-Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma
Anas Younes
[Protocol 16-006]

Prior Treatment (Relapsed/Refractory)

A Phase II Study of RICE Chemotherapy with and without SGN19 in Patients with Recurrent or Persistent Diffuse B-Cell Lymphoma
Craig H. Moskowitz
[Protocol 16-008]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Craig S. Sauter
[Protocol 14-145]

A Phase I Study of Immunotherapy with Genetically Modified T Cells to Treat Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 15-295]

A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
Nikoletta Lendvai
[Protocol 14-105]

Hodgkin Lymphoma

Mantle Cell Lymphoma

Burkitt’s Lymphoma

Richter’s Transformation

T Cell Lymphoma

HIV+ Lymphoma

Primary CNS Lymphoma or PTL

Waldenstrom’s Macroglobulinemia

Phase I Trials

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase I Study of JNJ-64052781 in Patients with Recurrent or Persistent B-Cell Cancers
Anas Younes
[Protocol 15-125]

A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Craig S. Sauter
[Protocol 14-145]

A Phase Ib/II Study of Mocetinostat plus Brentuximab Vedotin in Patients with Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 14-232]

A Phase I/II Study of Lenalidomide plus Combination Chemotherapy to Treat Newly Diagnosed Stage II-IV Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-515]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]